This illustration, taken on September 9, 2020, features a test tube labeled vaccine in front of the AstraZeneca logo.
Dadu Rouvik | Reuters
London – British pharmaceutical giant AstraZeneca said on Monday that an interim analysis of clinical trials showed that its coronavirus vaccine has an average efficacy of 70% to protect against the virus.
This comes after a string of encouraging vaccine results in recent weeks, followed by late-stage trial readouts from Pfizer-BioNotech and Modern.
It is hoped that a covid vaccine may help end the coronovirus epidemic that has claimed more than 1.3 million lives worldwide.
AstraZeneca said its vaccine, developed in collaboration with the University of Oxford, was assessed in two different dosage regimens.
One showed an effectiveness of 90% when test participants received a half dose, followed by a full dose of at least one month. The dose of other doses showed 62% efficacy when given as two full doses at least one month apart.
The combined analysis from both dosing regimens found an average vaccine effectiveness of 70%. No hospital or serious cases of the disease occurred among participants receiving the vaccine.
A total of 131 Kovid-19 cases were evaluated in the interim analysis.
AstraZeneca CEO Pascal Soriot said the development marked an “important milestone” in the fight against the global health crisis.
“The efficacy and safety of this vaccine confirms that it will be highly effective against COVID-19 and will have an immediate impact on this public health emergency,” Sorot said.
“In addition, the vaccine’s simple supply chain and our no-profit pledge and commitment to comprehensive, equitable and timely access mean it will be affordable and available globally, supplying hundreds of millions of doses upon approval. “
AstraZeneca said it would immediately regulate the submission of data to health authorities around the world which is a framework for conditional or preliminary approval.
“These findings indicate that we have an effective vaccine that will save the lives of many people,” Professor Andrew Pollard, chief investigator of the Oxford Vaccine Trial, said in a statement.
“Encouragingly, we have found that one of our dosing regimens can be approximately 90% effective and if this dosing regime is used, more people may be vaccinated with the vaccine supply employed.”
This is a breaking news story, please check back later.